Talc Litigation and Tariff Costs: J&J’s 2026 Margin Overhang

Talc special master decision keeps legal risk alive, not eliminated: What it means for J&J cash flows

Talc litigation remains an unresolved overhang for J&J, even as management frames procedural setbacks as favorable. In its ongoing case over discontinued talc products linked to ovarian and cervical cancers, a court-designated special master excluded certain expert witnesses while allowing plaintiffs evidence to proceed, prolonging the path to finality. [2] Financially, that matters because outcomes could still drive cash outflows through settlements or damages, and because legal uncertainty can pressure buyback and capital allocation even when operating momentum is strong.

Tariffs add roughly $500M to MedTech costs, and linearity is not certainty: Why margins could wobble

J&J explicitly included an estimated $500 million of tariff-related costs within its MedTech segment in 2026 planning, and it expects tariffs to be relatively linear compared with last year. [2] The business logic is straightforward: higher imported or compliance costs can compress MedTech margins unless pricing, mix shifts, or productivity offset them, and “linear” still implies a continuing headwind rather than a reset to baseline.

Patent-cliff progress is real, but legal and tariff shocks can delay the earnings-to-cash translation

J&J says it is putting the Stelara loss-of-exclusivity behind it, with 2025 sales at $94.2 billion and 2026 revenue guidance targeting $99.5 billion to $100.5 billion. [1] [2] The financial risk is timing and durability: even if Innovative Medicine and MedTech rebounds are on track, talc and tariff pressures can interrupt the expected translation from revenue growth into stable adjusted earnings and cash generation, especially if costs rise or litigation timing extends beyond expected windows. [2]